These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 20234782)

  • 1. Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy.
    Lin Y; Mousa SS; Elshourbagy N; Mousa SA
    Vasc Health Risk Manag; 2010 Mar; 6():73-85. PubMed ID: 20234782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic dyslipidemia: a practical guide to therapy.
    Tovar JM; Bazaldua OV; Loffredo A
    J Fam Pract; 2008 Jun; 57(6):377-88. PubMed ID: 18544321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
    Chrysant SG; Ibrahim M
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
    Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM
    Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH; Bachenheimer BS
    Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
    Schulz I
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):344-59. PubMed ID: 16767301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins.
    Gaw A
    Cardiovasc Drugs Ther; 2003 Jan; 17(1):53-62. PubMed ID: 12843687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
    Sharma RK; Singh VN; Reddy HK
    Vasc Health Risk Manag; 2009; 5():793-9. PubMed ID: 19812691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum high density lipoprotein cholesterol levels in Chinese healthy subjects and patients with certain diseases.
    Cai HJ; Li ZX; Yang SM
    Atherosclerosis; 1982 Jun; 43(2-3):197-207. PubMed ID: 7115460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.